SCT; toxicity; drug interaction Busulfan (Bu) in combination with cyclophosphamide (Cy), has gained increasing popularity as an alternative to preparative regimens containing total body irradiation (TBI) in patients undergoing stem cell transplantation (SCT) for both malignant and nonmalignant disorders. 1 The antileukemic effects and the therapeutic efficacy of the Bu/Cy regimens are considered to be equivalent to Cy/TBI. However, treatment related toxicity is still the dose-limiting factor. 2 Bu is given orally, usually as 1 mg/kg every 6 h over four consecutive days. The disposition of the drug has been studied in both children and adults. Many studies have shown the wide inter-and intra-patient variability in plasma concentrations. Many factors have been pinpointed as an explanation for the variation in drug disposition including bioavailibility, stage of disease, age, chronopharmacology and liver function. [3] [4] [5] Bu is mainly metabolized in the liver. Some interactions with other drugs such as phenytoin, itraconazole and ketobemidone have been reported to alter Bu disposition. An alteration in the pharmacokinetics of the drug may change its pharmacodynamics and as a consequence an increase in toxicity and/ or a higher relapse rate may be observed. [6] [7] [8] Hepatic veno-occlusive disease (VOD) is the most frequent life-threatening complication observed after high-dose Bu. 9, 10 Other complications, such as interstitial pneumonia (IP), hemorrhagic cystitis, cataracts, convulsions, alopecia and mucositis have been reported as regimenrelated toxicities after high-dose Bu. 11, 12 To decrease the wide variability in Bu pharmacokinetics, several limited sampling models for monitoring plasma levels of Bu have been established. 13, 14 Owing to an increase in the use of matched-unrelated donors for SCT a lower survival rate compared to HLAidentical siblings and an increased rate of acute and chronic graft-versus-host disease (GVHD) has been observed. Modified protocols with prophylactic drugs against GVHD including metronidazole 15, 16 have been suggested. Metronidazole has been used for a long time as prophylaxis against anaerobic infections, and parasites. 17 Metronidazole is known to be metabolized through the cytochrome P-450 system. The aim of the present study was to illustrate an interaction between Bu and metronidazole, which results in an increase in Bu concentrations leading to an increase in treatment related toxicity.
Patients and methods
Between May 2000 and October 2000, 14 adults diagnosed with leukemia (AML, CML) underwent allogeneic SCT at the Huddinge University Hospital. Patients were conditioned with Bu/Cy prior to SCT. Bu was administered orally at a dose of 1 mg/kg every 6 h over four consecutive days, on day À9 to day À5 prior to transplant. At 24 h after the last Bu dose, the patients were treated with Cy 60 mg/ kg, which was administered on days À4 and À3. During Cy infusion, alkalinization, forced diureses and uromitexan was given. The Bu concentrations were measured as AUC based on three-time concentration points (1, 3 and 6 h) after the administration of the first dose as described in Hassan et al. 14 The trough levels of Bu were determined as a mean minimum concentration, that is one sample was taken immediately before each dose. The dose was adjusted if required to obtain trough levels of about 500 ng/ml since AUC and trough levels are well correlated. 13 Posttransplant immunosuppression to prevent GVHD consisted of four doses of methotrexate combined with cyclosporine. 18 Intravenous cyclosporine was started on day À1 at a dose of 5 mg/kg/day for patients receiving grafts from unrelated donors, and 1 mg/kg/day for patients with HLA-identical sibling donors. On the day of SCT, cyclosporine was reduced to 3 mg/kg/day in recipients of unrelated grafts. On day +1, or as soon as the patient could take cyclosporine orally, 6.25 mg/kg/day was given to patients having unrelated transplants. Siblings received 1.5 mg/kg/day. During the first month, blood cyclosporine levels were kept at 200-300 ng/ml in recipients of unrelated grafts and 100-200 ng/ml in patients with sibling donors. 19 Recipients of unrelated grafts were treated with thymoglobuline (IMTIX Sangstat, Lyon, France) at a total dose of 10 mg/kg given from day À5 to day À1. Treatment and supportive care have been previously published. 19 None of the patients had any hepatic dysfunction or any other hepatic abnormality prior to SCT. Moreover, none of the patients of any group experienced severe infection prior to transplantation.
Study design
Group A received metronidazole 3 Â 400 mg (p.o.) pretransplant to prevent Clostridium difficile infection and post-transplant as prophylaxis against GVHD. Metronidazole was given with high-dose Bu treatment to five patients. Group B received Bu without metronidazole for 2 days followed by 2 days of Bu and metronidazole (n ¼ 9). The metronidazole was administered 48 h after the start of Bu. Bu trough levels were compared in both Groups A and B with a retrospective Group C (n ¼ 10) who had been transplanted at Huddinge University Hospital in 1999 and were conditioned with Bu/Cy without metronidazole. Details on patient characteristics and type of transplantation among patients are shown in Table 1 .
Sample collection and Bu analysis
Heparinized blood samples (3-5 ml) were obtained from central venous catheter (CVC) immediately before each dose of Bu. Plasma was separated at 2000 g and frozen at À201C until analysis. Plasma samples containing Bu were thawed and the internal standard 1,5-bis(methanesulfonoxy) penthane was added. Bu and the internal standard were converted to 1,4-diiodobutane and 1,5-diiodopentane, respectively. Bu levels were measured using gas chromatography (GC) with electron-capture detection as described previously. 20 
Liver status
The liver function tests, that is AST, ALT and bilirubin were followed throughout the study.
VOD was diagnosed on the basis of clinical signs -that is the presence of hyperbilirubinemia (total serum bilirubin 434 mmol/l) and the development of two of the following signs during the first 21 days post-transplant: weight gain 45% from preconditioning baseline weight, ascites and/or hepatomegaly. VOD severity was graded as mild (selflimiting and requiring no treatment), moderate (clinical abnormalities which required pain control and/or diuretics for fluid retention) and severe VOD (clinical abnormalities which required therapy and did not resolve by day 100 post-transplant or ended in death).
Statistical analysis. The trough levels of Bu, that is the mean minimum concentrations (based on 13 measured blood samples from each patient, one sample taken immediately before each dose), were compared between Group A and Group C. The trough levels of Bu in Group B based on samples collected between 18 and 54 h (before the administration of metronidazole) were compared with the levels obtained within the same group after the administration of metronidazole (60-90 h). Bu levels observed in Group B before and after the administration of metronidazole were compared with those found in both Groups A and C, respectively. The non-parametric, Mann-Whitney test was used to compare the groups. Results were expressed as mean7s.d. The statistical software, Instat version 3.0 and Graph Prism version 3.0 (GraphPad Software Incorporated, San Diego, USA) were used.
Results
The mean trough levels of Bu for all patients are shown in Table 2 . All trough levels are adjusted to a Bu dose of 1 mg/ kg/dose, because of the dose adjustment during the treatment. Group A, in which metronidazole was administered during the entire conditioning, had significantly (Po0.001) higher concentrations of Bu during the 4 days with a mean value of 9487280 ng/ml compared with the control group (507775 ng/ml). In Group B, receiving metronidazole only for 2 days, Bu concentrations were detected to 452768 ng/ml up to 54 h after start of Bu treatment. The addition of metronidazole resulted in a significant (o0.0001) increase in Bu trough level to 807790 ng/ml (measured from 60 to 90 h). No significant difference in Bu trough levels was observed between the control group and the concentrations measured during the first period (0-54 h) in Group B. The trough levels of Bu are shown in Figure 1 . The actual values of the trough levels for each patient are given in Table 3 , and the mean value of the dose for each patient during treatment is also shown. 
Regimen-related toxicity
In Group A where metronidazole was administered during Bu therapy, all five patients had elevated liver function tests. One patient developed hemorrhagic cystitis. Three patients were diagnosed as having VOD (one mild and two moderate to severe) according to the Jones criteria. 21 The patients with severe VOD required intensive treatment and one patient died of multi-organ failure. One patient developed meningitis. All five patients showed clinical signs of mucositis varying from grade II to IV (Table 3) .
In Group B, five of nine patients had elevated liver bilirubin levels and only one had elevated ALT and AST values. One patient developed hemorrhagic cystitis, and six of nine developed mucositis grades II-IV. None of the patients developed VOD (Table 3) . In Group C, three patients had elevated AST values. Two patients developed hemorrhagic cystitis. None of the patient developed VOD and only one developed mucositis grade II (Table 3) .
Discussion
Use of Bu in combination with cyclophosphamide as a conditioning regimen prior to SCT has increased during recent years. A number of studies have been able to demonstrate the high inter-and intrapatient variation in drug disposition and some of the factors underlying this variability have been pointed out, including disease, age, bioavailability, liver status prior to transplantation, Table 3 Plasma trough levels of Bu in ng/ml for the different groups, adjusted to a dose of 1 mg/kg and actual trough level. Dose/kg is a mean dose in mg/kg for each patient. Group A: Bu and metronidazole, Group B: Bu for 2 days followed by Bu and metronidazole for 2 days, Group C: Despite the small number of patients in the present study, we observed that the administration of metronidazole during Bu therapy resulted in dramatic increases in Bu concentrations and an increase in treatment-related toxicity. Vassal et al have shown that a high systemic exposure to Bu resulted in a significant increase in the risks for both VOD and neurotoxicity. 10, 22 Grochow et al have determined the limit of Bu levels that are correlated with an increased incidence of VOD. 9 In many oral drugs with high hepatic clearance the intravenous form of administration is most likely to solve the problems with first pass effect and decrease interpatient variability. However, Bu is known to have low clearance, which suggests that an intravenous form would not solve all problems with interpatient variability. On the other hand, the intravenous formulations of Bu available are limited and still in clinical trials. [23] [24] [25] [26] To decrease the inter-patient variability, the only option currently available is to monitor Bu levels and adjust the dose. 13, 14 Many limited sampling models have been developed to increase the accuracy and reliability of dose adjustment during high-dose therapy of Bu. Dose adjustment is the most frequently used strategy today.
Owing to an increased use of unrelated donors, an increase in GVHD was observed during the recent years. To decrease the risk for GVHD, prophylactic treatment including metronidazole was introduced to some transplantation protocols. 15, 16 Metronidazole is an antimicrobial drug widely used in the treatment of anaerobic bacteria. 17 Metronidazole is mainly eliminated by hepatic oxidation through the cytochrome P-450 oxidative system. 27 However, metronidazole is also an inhibitor of some cytochrome P-450 subfamilies such as CYP 3A4 and CYP 2C9. 28 In rats, in vitro as well as in vivo conjugation is the predominant route of metabolism of metronidazole. 29 However, in man the oxidative formation of hydroxymetronidazole and metronidazole acetic acid are the major routes of elimination.
Metronidazole has been shown to interact with a number of other drugs which are metabolized mainly through CYP 2C9. [30] [31] [32] Hassan et al and Marchand et al have shown that Bu 33, 34 is eliminated enzymatically by a reaction with glutathione to form a sulfonium ion of GSH in rat liver. Recent studies showed that human purified GST is an important catalyst for Bu conjugation with GSH and that Bu is a better substrate for GST than other alkylating agents such as melphalan and chlorambucil. 35 Recently published results by the same authors showed that young children are better metabolizers of Bu compared to adults, which was suggested as being due to higher levels of GST in children than in adults. 36 The urinary metabolites isolated in man and rat 37, 38 suggested that the sulfonium ion is rapidly decomposed in vivo, resulting in the formation of tetrahydrothiophene (THT). THT is a lipophilic compound and has to be oxidized before its excretion. The oxidation of THT was shown to yield THT-1 oxide, sulfolane and 3-hydroxysulfolane. These metabolites have been isolated and identified in both rats and humans. 33, 37 Damani and Houdi 39 have shown that cytochrome P-450 can play an important role in the oxidation of THT and other xenobiotics containing sulfur. The oxidation of tetrahydrothiophene most probably occurs via the cytochrome P-450 system. Sherratt and Damani 40 have reported that microsomal activity in rat hepatocytes declines by 35% of its baseline activity using THT as a substrate. Considering the high dose of Bu used clinically and the long exposure time of 4 days, Bu therapy can undoubtedly deplete GSH levels.
Despite the different metabolic pathways of Bu compared to metronidazole, we observed significantly higher levels of Bu when patients were treated with metronidazole. Moreover, the addition of metronidazole 48 h after the start of Bu treatment resulted in significant increase in Bu concentrations. The high Bu concentrations found in the present study may be explained by the low hepatic glutathione content. GSH is required for Bu metabolism. However, glutathione functions also as a scavenger for metronidazole reactive metabolites as demonstrated by Larsson et al. 41 On the other hand, an increase in the risk for VOD may be because of both an increase in Bu levels as well as an increase in the reactive metabolites of metronidazole since Bu therapy certainly diminish hepatic glutathione. Martelli et al 42 demonstrated that DNA damage caused by metronidazole in hepatocytes is increased by GSH depletion. We have recently shown that the administration of Cy, shortly after Bu, has resulted in an increase in VOD incidence compared to that when the time interval between both drugs was prolonged. 43 Cy is metabolized through the cytochrome P-450 system; however, the first metabolite of Cy (4-hydroxycyclophosphamide) requires glutathione for detoxification. Shulman et al 44 have found that the treatment of dogs with BSO, a glutathione synthetase inhibitor, before treatment with alkylating agents, caused a higher incidence of VOD.
In conclusion, the administration of metronidazole as prophylactic treatment against GVHD during high-dose Bu therapy leads to an increase in Bu concentrations. An increase in Bu levels most likely increases the risk of VOD and treatment-related toxicity in SCT patients. It is of clinical importance, especially in young children, to use drugs with less interaction with Bu and/or Cy. Moreover, it is important to use drugs that do not decrease the levels of GSH and/or its transferases. Glutathione may play an important role in protecting hepatocytes during Bu therapy, as is the case with other alkylating agents.
